REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
24/03/2025
Voltar para busca
Dado oficial do USPTO
INNOVENT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
64
Atualização mais recente
25/03/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
16/04/2018
Data de registro
24/03/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/03/2020
Última transação
25/03/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
CN
Examinador
ROACH, APRIL
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The trademark consists of the English letters of "I", "N", "N", "O", "V", "E", "N" and "T", in which the English letter "O" is designed by two symmetrical arcs. The mark has no particular meaning when taken as a whole.
Titulares e representantes
Titulares
Innovent Biologics (Suzhou) Co., Ltd.
Representantes
Anessa Owen Kramer Honigman LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Medicines for human purposesantibody preparationsprotein preparationsblood preparationshormonesenzymestoxoidsorganic compounds and hemopoietic growth factorsmedicines for the treatment of tumorophthalmologic diseasesimmunological mediated diseasesmetabolic diseasesblood diseasesdiabetesendocrine diseasereproductive system diseasecentral and peripheral nervous system diseasehereditary diseasesantiviral drugs; Pharmaceutical preparationsantibody preparationsprotein preparationblood preparationshormonesenzymestoxoidsorganic compounds and hemopoietic growth factorsmedicines for the treatment of tumorophthalmologic diseasesimmunological mediated diseasesmetabolic diseasesblood diseasesdiabetesendocrine diseasereproductive system diseasecentral and peripheral nervous system diseasehereditary diseasesantiviral drugs; Vaccines; drugs for medical purposesantibody preparationsprotein preparationblood preparationshormonesenzymestoxoidsorganic compounds and hemopoietic growth factorsmedicines for the treatment of tumorophthalmologic diseasesimmunological mediated diseasesmetabolic diseasesblood diseasesdiabetesendocrine diseasereproductive system diseasecentral and peripheral nervous system diseasehereditary diseasesantiviral drugs; Biological preparations for medical purposesantibody preparationsprotein preparationblood preparationshormonesenzymestoxoidsorganic compounds and hemopoietic growth factorsmedicines for the treatment of tumorophthalmologic diseasesimmunological mediated diseasesmetabolic diseasesblood diseasesdiabetesendocrine diseasereproductive system diseasecentral and peripheral nervous system diseasehereditary diseasesantiviral drugs; Diagnostic preparations for medical purposes; Biological tissue cultures for medical purposes; Chemical reagents for medical purposes; all of the aforesaid excluding goods in gaseous formgoods related to nitric oxideveterinary productspreparationsreagentsmedicine for animal health
Publicações
Histórico de despachos e eventos da marca no USPTO.
64 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/07/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/07/2020
FIMP
FINAL DISPOSITION PROCESSED
10/07/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
25/06/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/06/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
24/03/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/01/2020
PUBO
PUBLISHED FOR OPPOSITION
07/01/2020
GPNX
NOTIFICATION PROCESSED BY IB
03/01/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
18/12/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
18/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/12/2019
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
13/12/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/12/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
04/12/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/12/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
04/12/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/12/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
27/11/2019
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
27/11/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/11/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/11/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/11/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/11/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/11/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/10/2019
GAUN
NOTIFICATION OF NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
28/10/2019
GAUD
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
28/10/2019
NAUD
REPORT UNRESPONSIVE AMENDMENT - COMPLETED
28/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/10/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
25/10/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
25/10/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
25/10/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/08/2019
GNFR
FINAL REFUSAL E-MAILED
13/08/2019
CNFR
FINAL REFUSAL WRITTEN
13/08/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
16/07/2019
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
18/01/2019
DMCC
DATA MODIFICATION COMPLETED
12/12/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/12/2018
GNSL
LETTER OF SUSPENSION E-MAILED
11/12/2018
CNSL
SUSPENSION LETTER WRITTEN
11/12/2018
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/12/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/11/2018
DMCC
DATA MODIFICATION COMPLETED
26/11/2018
ALIE
ASSIGNED TO LIE
21/11/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/11/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/11/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/11/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/11/2018
RFNT
REFUSAL PROCESSED BY IB
07/09/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
20/08/2018
RFRR
REFUSAL PROCESSED BY MPU
20/08/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
04/08/2018
CNRT
NON-FINAL ACTION WRITTEN
03/08/2018
DOCK
ASSIGNED TO EXAMINER
03/08/2018
MAFR
APPLICATION FILING RECEIPT MAILED
06/07/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/07/2018
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
25/06/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/06/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace INNOVENT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.